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Modulation of plasminogen activator inhibitor-i in vivo: A new
mechanism for the anti-fibrotic effect of renin-angiotensin
inhibition
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Modulation of plasminogen activator inhibitor-i in vivo: A new mech-
anism for the anti-fibrotic effect of renin-angiotensin inhibition. We
examined the potential of in vivo linkage of plasminogen activator
inhibitor-i (PAT-i) and angiotensin IT (Ang TI) in the setting of endothe-
hal injury and sclerosis following radiation injury in the rat. PAT-i is a
major physiological inhibitor of the plasminogen activator (PA)/plasmin
system, a key regulator of fibrinolysis and extracellular matrix (ECM)
turnover. PAT-I niRNA expression in the kidney was markedly increased
(9-fold) at 12 weeks after irradiation (P <0.001 vs. normal control). In situ
hybridization revealed significant association of PAT-i expression with
sites of glomerular injury (signal intensity in injured vs. intact glomeruli,
P < 0.001). Angiotensin converting enzyme inhibitors (ACEI, captopril or
enalapril) or angiotensin II receptor antagonist (AuRA, L158,809) mark-
edly reduced glomerular lesions (thrombosis, mesangiolysis, and sclerosis;
sclerosis index, 0 to 4+ scale, 0.49 0.20 in untreated vs. 0.05 0.02,
0.02 0.01, 0.04 0.02 in captopril, enalapril and AuRA, respectively, all
P < 0.01 vs. untreated). Further, ACEI and AuRA markedly attenuated
increased PAT-I mRNA expression in the irradiated kidney (36, 19 and
20% expression, respectively, for captopril, enalapril and AITRA, com-
pared to untreated irradiated kidney, P < 0.05, < 0.01, <0.01). This effect
was selective in that neither tissue-type nor urokinase-type PA mRNA
expression was affected by these interventions. Thus, we speculate that
inhibition of the renin-angiotensin system may ameliorate injury following
radiation by accelerating fibrinolysis and ECM degradation, at least in
part, via suppression of PAT-i expression. In summary, inhibition of Ang
IT, in addition to its known effects on vascular sclerosis, may also by its
novel effect to inhibit PAT-i, lessen fibrosis following endothelial/throm-
botic injury.
The renin-angiotensin system (RAS) plays a multifaceted role
in the regulation of vascular homeostasis. Angiotensin II (Ang II)
regulates vascular tone by two different mechanisms, including
immediate effects as a vasoconstrictor and delayed effects on
vascular structure. Inhibition of the RAS not only decreases
systemic blood pressure, but also ameliorates glomerular sclerosis
and interstitial fibrosis in experimental animal models [1, 2]. In
addition, recent reports suggest that RAS also acts directly on
vascular endothelial cells, affecting proliferation [3], stimulating
synthesis of prostaglandin [4], endothelin [5], and modulating the
plasminogen activator (PA)/plasmin system [6—8].
Plasminogen activator inhibitor-l (PAl-i) is the main physio-
logical inhibitor of tissue-type plasminogen activator (t-PA) and
urokinase-type plasminogen activator (u-PA), and thus plays an
important role in regulation of the PA/plasmin system. Elevated
levels of PAl-I have been implicated in the pathogenesis of
thrombotic diseases such as hemolytic uremic syndrome [9], and
may contribute to the risk of reinfaretion in patients with a
previous myocardial infarction [10]. The PA/plasmin system is not
only a key regulator of fibrinolysis, but also participates in
extracellular matrix (ECM) degradation, since plasmin can cleave
most ECM proteins [11]. This raises the possibility that the
PA/plasmin system may be involved in tissue remodeling/fibrosis,
where accumulation of ECM plays a key role.
We recently observed that Ang TI stimulates expression of
PAl-i in cultured aortic endothehial cells [61. Further, infusion of
physiological amounts of Ang IT promotes a rapid and dose-
dependent selective increase in PAl-i in humans [8]. Conversely,
angiotensin converting enzyme inhibitor (ACEI) and angiotensin
II receptor antagonist (AIIRA) have been shown to increase u-PA
activity in cultured aortic endothelial cells [7]. More recently,
Hamdan et al have demonstrated that ACET suppressed the
increased PAT-i expression in the neointima of balloon-injured
rat aorta [12]. These data suggest potential links between the RAS
and PA/plasmin systems.
Of interest, activation of the RAS is thought to play a role in the
development of extravascular fibrosis. Furthermore, ACEI has
been shown to ameliorate scarring after radiation in the kidney
[13], as well as lung [14] and skin [15]. We therefore used the
radiation nephropathy model where early endothelial injury and
thrombosis are followed by sclerosis, as a tool to study evolution
of these injuries. Specifically, we investigated whether the inter-
actions between the RAS and PA/plasmin systems observed in
vitro are also present in vivo, and if so, whether this interaction has
consequences for thrombosis and tissue remodeling/fibrosis after
vascular injury.
Methods
Experimental animals
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Adult male Sprague-Dawley rats (180 to 206 g) were studied.
Bilateral kidney irradiation was accomplished while rats were
under anesthesia (pentobarbital, 50 mg/kg body wt i.p.), with a
single dose of 12 Gy at a dose rate of 150 rad/min using a 60Co
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y-ray irradiator. Rats were fed with standard rat chow after
recovery. To assess the stages of development of radiation ne-
phropathy, four rats were sacrificed at each time point at two,
four, and eight weeks after irradiation. In addition, 39 irradiated
rats were divided into untreated (N = 11) and treated groups,
receiving either captopril [500 mg/liter drinking water (DW);
Bristol Myers Squibb, Inc., Princeton, NJ, USA,N = ii], enalapril
maleate (200 mg/liter DW; Merck Research Laboratories, Rah-
way, NJ, USA; N = 6), or Ang II receptor antagonist (AuRA)
(L158,809, 80 mg/liter DW, Merck, N = 11). L158,809 is an Ang
II type I receptor antagonist that shows high affinity and selectivity
for the type I receptor with no agonist activity [1]. Sham-irradiated
control rats (N = 6) were also studied. In each group 6 rats were
sacrificed at 12 weeks, and in irradiated groups without further
treatment or treated with captopril or AuRA, an additional 5 rats
were sacrificed at 24 weeks after irradiation.
Analysis of kidney function
Mean arterial pressure (MAP) was measured on the day of
sacrifice under anesthesia with mactin (Byk, Gulden Konstanz,
Germany; 80 mg/kg body wt i.p.) by a transducer recorder (Gould
2400S) connected to a catheter placed in the left femoral artery.
Serum creatinine was measured by a Monarch centripetal ana-
lyzer. Proteinuria was measured by the Coomassie brilliant blue
method using urine samples collected for 24 hours prior to
sacrifice.
Histological study and analysis
Tissues were fixed overnight in 4% paraformaldehyde, routinely
processed and embedded in paraffin and 3 to 4 ,am sections were
used for periodic acid-Schiff stain, Masson stain, Jones stain, and
in situ hybridization studies. For electron microscopy, tissues from
3 rats in non-treated irradiated group at week 12 were fixed in
gluteraldehyde and postfixed in uranyl acetate, osmium tetraoxide
and embedded in Spurrs for thin sectioning. Sections were viewed
in a Philipps 300 transmission electron microscope.
A semiquantitative score (sclerosis index, SI) was used to
evaluate the degree of glomerular sclerosis. Sclerosis was defined
as collapse and/or obliteration of the glomerular capillary tuft
accompanied by hyaline material and/or increase of matrix.
Glomerular sclerosis was assessed by scoring severity of sclerosis
on all glomeruli on a single section of the kidney. Severity of
sclerosis for each glomerulus was graded from 0 to 4+ as follows:
0 represented no lesion, 1 + represented sclerosis of less than 25%
of the glomerulus, while 2+, 3+, and 4+ represented sclerosis of
25 to 50, 50 to 75 and 75 to 100% of the glomerulus, respectively.
A whole kidney average sclerosis index was obtained by averaging
scores from all glomeruli on one section. All sections were
examined without knowledge of the treatment protocol.
DNA probes fur mouse t-PA, u-PA and PAl-I
Mouse t-PA, u-PA and PAl-i cDNA fragments were prepared
by reverse transcription PCR. Total RNA was extracted from the
kidney of adult C57BL/6 mice by the RNAzoI'MB method
(TEL-TEST Inc., Friendwood, TX, USA). For preparation of
u-PA probe, RNA was extracted from normal mouse kidney. For
t-PA and PAl-i probes, RNA was extracted from mouse kidney
four hours after the i.p. injection of LPS 50 j.tg (E. coli 011; Sigma
Chemical Co., St. Louis, MO, USA). The purified RNA was
reverse transcribed to cDNA using random primer and reverse
transcriptase (SuperScript RT; GIBCO, BRL, Grand Island, NY,
USA). PCR was performed on the template cDNA using primer
sets, each of which encompasses protein coding regions of mouse
t-PA, u-PA and PAl-i cDNA (amplified cDNA fragment size 365
bp, 501 bp and 386 bp, respectively). The amplified cDNA
fragments were inserted into pCRTMII plasmid by TA cloning kit
(Invitrogen, San Diego, CA, USA). Fidelity of the cDNA frag-
ments was confirmed by DNA sequence analysis. Mouse interleu-
kin-1f3 (IL-lp) eDNA and rat basic fibroblast growth factor cDNA
were prepared by reverse transcription PCR of extracted RNA
from cultured RAW 264.7 cells and rat kidney, respectively.
Mouse platelet-derived growth factor-B chain (PDGF-B) cDNA
was a gift from Dr. C.D. Stiles. Mouse transforming growth
factor-f31 (TGF-J31) cDNA was a gift from Dr. H.L. Moses.
Mouse tumor necrosis factor-n (TNF-a) cDNA (pMuTNF) was
purchased from American Type Culture Collection (Rockville,
MD, USA). Human glyceraldehyde 3-phosphate dehydrogenase
(G3PDH) eDNA was purchased from Clonetech (San Francisco,
CA, USA).
Northern blot analysis
Total RNA was extracted from the cortex of the left kidney by
RNAz01rMB method. Ten micrograms of total RNA was loaded
into each lane and was fractionated by electrophoresis in 1%
agarose gel and transferred to nylon membranes. Each cDNA
probe was labeled with 32P-dATP and hybridization was per-
formed in buffer (4 x SSCP, I x Denhardt's, 1% SDS, 100 g/ml
denatured salmon sperm DNA and 10% dextran sulfate) over-
night at 65°C. Membranes were washed twice in 2 )< SSC for 10
minutes at room temperature and once in 0.2 X SSC, 0.1% SDS
for 20 minutes at 65°C. Autoradiography was performed at —70°C
for approximately 18 to 42 hours. Autoradiographs were scanned
by image scanner JX-330 (Hitachi, Japan) and intensity of signals
was measured by NIH Image (National Institute of Health,
Bethesda, MD, USA).
In situ hybridization study
35S-labeled sense and antisense riboprobes for t-PA, u-PA and
PAl-I were prepared by transcription of the pCRTMII plasmid
with insertion of each cDNA fragment by SP6 or T7 RNA
polymerase (Promega, Madison, WI, USA). Sections were de-
waxed in xylene, hydrated in graded ethanols and then refixed in
4% paraformaldehyde. After treatment by proteinase K and
triethanolamine/acetic anhydride, sections were dehydrated in
ethanol and air dried. Hybridization was done in buffer (50%
formamide, 10% dextran sulfate, 8 mrvi DTT, 0.2 mg/mI tRNA,
300 mM NaCI, 10 mvi Tris-HCI, 5 mM EDTA, 0.02% polyvinylpy-
rolidone, 0.02% Ficoll and 0.02% BSA) overnight at 50°C.
Sections were washed in 2 X SSC, 50% formamide for 20 minutes
at 65°C, treated with RNase at 37°C for 30 minutes, washed in 2 X
SSC and 0.1 x SSC each twice for 10 minutes at 65°C. Sections
were then dehydrated in ethanol and air-dried, dipped in photo-
graphic emulsion and exposed at 4°C for about two weeks. The
sections were developed with D-19 developer (Kodak, Rochester,
NY, USA) and counterstained with toluidine blue. Light micro-
scopic assessment of sclerosis, thrombosis and mesangiolysis was
done in the sections adjacent to sections for in situ hybridization.
The number of PAl-i positive cells per glomerular tuft (defined as
grains  10/cell) was then correlated with morphological findings
in the same glomeruli.
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Statistical methods
Results are expressed as mean standard error (su). Compar-
isons between two groups were made using the unpaired t-test.
Morphologic findings were compared by the Mann Whitney
U-test. Statistical significance was set at P < 0.05.
Results
Renal dysfunction in radiation nephropathy
Irradiated rats without further treatment did not develop
proteinuria at weeks 1, 2, or 4 after irradiation. At week 8, one of
four irradiated rats developed proteinuria (64.1 mg/day). At week
12, all irradiated rats without further treatment developed pro-
teinuria (mean 78 27 mg/day, P < 0.001 vs. control group; Fig.
1). MAP in this irradiated group at week 12 did not differ
significantly from sham irradiated control group (115 6 mm Hg
vs. 112 4 mm Hg, respectively, P = NS; Table 1). Serum
creatinine levels in non-treated irradiated group at week 12 were
significantly higher than control group (0.65 0.02 mg/dl vs.
0.49 0.03 mg/dl, P < 0.01), and increased further by 24 weeks
(1.52 0.32 mg/dl).
Morphological and in situ hybridization assessment of radiation
nephropathy
Eight weeks after irradiation, at a time when glomerular
sclerosis and interstitial fibrosis were not prominent, there was
swelling of endothelial cells in the glomerulus and peritubular
capillaries, together with glomerular thrombosis and fibrin depos-
its by light microscopy. These glomerular lesions were observed in
5 to 30% of glomeruli. The most extensive lesions were present in
the rat that developed proteinuria. At week 12, mild to moderate
focal and segmental glomerular sclerosis appeared, together with
focal areas of tubular atrophy and interstitial fibrosis (Fig. 2A).
Mesangiolysis was present in 28 9% (range 8 to 68%) of
glomeruli, and ranged from mild to severe with ballooning
aneurysmal dilatation. Thrombosis was present in 10 2% (range
4 to 14%) of glomeruli, mostly in association with mesangiolysis.
Mild sclerosis with segmental capillary collapse affected 22 6%
(range 10 to 44%) of glomeruli, and severe sclerosis was present
in 11 5% (range 2 to 30%) of glomeruli. At week 24, advanced
focal and segmental glomerulosclerosis affecting 64 9% (ranger
50 to 90%) of glomeruli, tubular dilation and interstitial fibrosis
were present (Fig. 2C).
Electron microscopic examination at week 12 showed wide-
spread glomerular endothelial cell swelling and vacuolization.
Rare areas of more severe endothelial damage were present with
segmental (< 10% of loops) detachments from the underlying
basement membrane. These areas exhibited marked increased
lucency of the lamina rara interna with increased fiocculent
material accumulated on the subendothelial aspect of the glomer-
ular basement membrane. No fibrin was detected in the tissue
examined by electron microscopy. Mesangiolysis, represented by
loosening of mesangial matrix material, was present. Frank lysis of
mesangial cells was not seen. Epithelial cells showed occasional
vacuolization and mild microvillous transformation, with largely
intact foot processes. Peritubular capillaries showed swelling of
endothelial cells. Arterioles and larger arteries were not system-
atically sampled.
In situ hybridization study revealed that glomeruli without
morphological injury by light microscopy (intact glomerulus)
showed signal levels (0.5 0.1 positive cells per glomerulus)
similar to control animal levels (0.4 0.1). In contrast, glomeruli
with sclerosis showed increased PAl-I mRNA expression (2.5
0.2, P < 0.001 vs. intact glomerulus), with trends to higher PAT-I
mRNA expression (3.9 0.3, P < 0.001 vs. intact glomerulus) in
glomeruli with severe sclerosis (SI  2). Glomeruli with mesan-
giolysis (2.9 0.2, P < t).001 vs. intact glomerulus) or thrombosis
(3.1 0.4, P < 0.001 vs. intact glomerulus) also showed higher
PAl-I mRNA expression. The highest expression of PAl-I
mRNA was seen in glomeruli with all three injuries (4.3 0.7,
P < 0.001 vs. intact glomerulus; Fig. 3).
Effect of ACEI5 and AuRA on proteinuria and histological
changes
Treatment normalized proteinuria. Irradiated groups treated
either with captopril (14 3 mg/day) or enalapril (12 2 mg/day)
had levels of proteinuria comparable to control group (16 2
mg/day). Similarly, AuRA also reduced proteinuria (10 2
mg/day, P < 0.05 vs. control; Fig. 1). Treatment also reduced
MAP following irradiation. At week 12, MAP was significantly
lower in treated than in non-treated irradiated or control groups
(Table 1), although serum creatirline levels were similar in treated
and untreated irradiated rats at this time point (Table 1). At 24
weeks after irradiation, serum creatinine levels tended to remain
lower in captopril (0.84 0.09 mg/dl) or AIIRA treated group
(0.84 0.11 mg/dl) than non-treated irradiated rats (1.52 0.32
mg/dl).
Histological changes were also attenuated by these treatments
(Fig. 2 B, D). SI was 0.05 0.02 in the captopril treated group,
0.02 0.01 in the enalapril treated group and 0.04 0.02 in the
n
*
Fig. 1. Proteinuria at 12 weeks after irradiation. Abbreviations are: No Rx,
no treatment; Capt, captopril; Enal, enalapril; AuRA, angiotensin II
receptor antagonist. P < 0.001 versus untreated irradiated group.
Oikawa ci a!: I'AI-l, Ang II and endoihelial inju,y 167
Table 1. Systemic parameters and glomerular sclerosis at 12 weeks after irradiation
Irradiated
No
Control treatment Captopril Enalapril AuRA
Body weight g 394 9 364 Ii 343 95 324 7°" 329 7°
MAP mm Hg 112 4 115 6 98 4°" 92 2°° 82 4°'
Serum creatinine mg/dl 0.49 0.03 0.65 0.02" 0.65 0.04k 0.63 0.02k 0.70 0.06"
Sclerosis index (0-4+ 0.03 0.02 0.49 0.20k 0.05 0.02° 0.02 0.01° 0.04 0.02°
scale)
P < 0.05, "P < 0.01, P < 0.001, vs. control group, "P < 0.05, P < 0.01, 'P < 0.001, vs. untreated irradiated group
AuRA treated group, significantly lower (each P < 0.01) than the
non-treated irradiated group (0.49 0.20), Mesangiolysis and
thrombosis were only rarely seen in the glomeruli of treated
groups.
t-PA, u-PA, PAl-i and cytokine/growth factor mRNA expression
and effects of Ang II inhibition
PAl-I mRNA levels assessed by Northern blot analysis in the
kidneys of the non-treated irradiated group increased at week 8
and increased further at week 12 (Fig. 4). PAl-I mRNA levels
were increased by 2.7-fold of control group at week 8 (P < 0.05)
and by 9.0-fold (P < 0.001) at week 12 by quantifying with
densitometric analysis corrected with ratio to G3PDH mRNA.
The increase of PAT-I mRNA at week 12 was markedly attenu-
ated by treatment (captopril 3.2-fold, enalapril 1.7-fold, AuRA
1.8-fold, respectively, P < 0.05, P < 0.01, P < 0.01 compared with
the non-treated irradiated group). By in situ hybridization, PAl-i
mRNA expression was markedly diminished in treated groups
compared to untreated irradiated group. Only occasional glomer-
uli with injury showed increased signal.
Neither t-PA nor u-PA mRNA levels in untreated irradiated
groups changed significantly from control group at any time point
studied. In situ hybridization showed diffuse glomerular signal for
t-PA in the kidney of control group, and this expression pattern
was not changed by irradiation or treatment. u-PA expression was
present only focally in tubules especially within the medulla, and
this expression pattern was not changed by irradiation or treat-
ment.
Because TGF-, PDGF, bFGF, TNF- and IL-ip are known to
stimulate PAl-i expression in cultured cells [16—20], we also
studied the expression of these factors. There was no detectable
mRNA expression of IL-1/3, TNF-cs and bFGF in kidneys from
any groups. There was no statistically significant difference in
PDGF-B mRNA levels between control, non-treated irradiated
and treated groups. TGF-/31 mRNA levels in the kidney of
non-treated irradiated group at week 12 was increased moderately
by 1.6-fold (P < 0.001) of control group, and this increase was
attenuated by treatment, although changes in the captopril
treated group did not reach statistical significance (captopril
1.4-fold, enalapril 1.1-fold, and AuRA 1.0-fold, respectively, P =
0.07, P < 0.01, P < 0.01, compared with non-treated irradiated
group). TGF-/31 mRNA was expressed diffusely by in situ hybrid-
ization in the glomeruli, tubules and interstitial cells of control
kidneys. In kidneys of non-treated irradiated group TGF-131
mRNA expression intensity appeared to be diffusely and mildly
increased, however, there was no appreciable difference in signal
between glomeruli with or without lesions.
Discussion
The RAS has multiple biologic effects on vascular tissues. Ang
II not only regulates vascular tone by inducing contraction of
vascular smooth muscle or mesangial cells, hut also promotes
proliferation and ECM protein synthesis directly or via induction
of growth factors, such as PDGF [21, 22] and TGF-f3 [23]. These
actions may play a particularly important role in determining
whether remodeling or fibrosis results after vascular injury. In
addition, we and others showed that RAS also modulates the
PA/plasmin system by acting directly on vascular endothelial cells,
inducing expression of PAl-I [6]. In the present study we observed
increased PAl-I mRNA expression in the kidney 12 weeks after
irradiation, when mesangiolysis, thrombosis and early stages of
glomerular sclerosis were present. We also found that PAT-I
expression localized to areas of mesangiolysis, glomerular sclero-
sis and capillary thrombosis. Thus, PAl-I mRNA expression was
closely associated with injury in the irradiated kidney. Moreover,
prevention of its expression correlated with amelioration of
progressive scarring. These findings support involvement of PAT-I
in the formation of thrombosis and accumulation of extracellular
matrix leading to fibrosis after endothelial injury. In support of
this concept, a very recent report showed direct evidence of PAT-i
involvement in bleomycin-induced lung fibrosis. In this model,
endothelial injury precedes fibrosis, similar to the evolution of
radiation injury in our model [24]. Mice with overexpression of
PAl-I developed more severe fibrosis than normal mice, while
PAl-I deficient mice developed less severe fibrosis.
Other components of the PA/plasmin system could theoreti-
cally also modulate these injuries. Of note, the key components of
the PA/plasmin system (t-PA, u-PA and PAl-I) are independently
regulated. LPS injection induces t-PA and PAT-I expression, but
decreases u-PA expression in the murine kidney [25]. Both bFGF
and TGF-f3 enhance expression of both PAl-i and u-PA in
cultured endothelial cells. However, the ratio of u-PA/PAl-I shifts
towards enhanced proteolysis in response to bFGF, but towards
antiproteolysis in response to TGF-p [16]. Whereas high dose
Ang II stimulates both t-PA and PAl-i expressions in cultured
smooth muscle cells [26], infusion of Ang II in humans induces
acute dose-dependent increase in plasma PAT-i levels, but has
little effect on plasma t-PA [8]. In the present study, treatment
with either ACETs or AuRA had a selective effect to markedly
decrease PAl-I mRNA levels in the irradiated kidney, while
neither t-PA nor u-PA mRNA levels were affected. PAT-I synthe-
sis appears to he regulated at the translational level, and PAl-i is
rapidly secreted once synthesized [11]. Previous studies show tight
links of PAl-i protein and mRNA [12, 27—29], and also of
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Fig. 2. Light microscopy of the kidney at 12 (A, B) and 24 (C, D) weeks after irradiation. Moderate focal and segmental glomerular sclerosis and mild
to moderate interstitial fibrosis were present in untreated irradiated kidneys at week 12 (A). At week 24, the kidney of untreated group showed advanced
glomerular sclerosis with severe tubular atrophy and interstitial fibrosis (C). These lesions were markedly reduced by treatment with Ang II inhibition
at both time points (B, captopril treated group; D, AuRA treated group). (Masson stain, A and B, x 100, C and D, X40). Reproduction of this figure
in color was made possible by a grant from Merck Research Laboratories, Rahway, New Jersey, USA.
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Fig. 3. PAl-i mRNA expression in the glomerulus of untreated irradiated group by in situ hybridization (A). The same glomerulus is shown in an adjacent
section by Jones stain (B). The glomerulus shows mesangiolysis, segmental sclerosis and capillary thrombosis, colocalizing with intense signal (X400).
Reproduction of this figure in color was made possible by a grant from Merck Research Laboratories, Rahway, New Jersey, USA.
fibrinolytic activity and PAT-i mRNA expression [30]. Thus, between PAs and PAT-i in the kidney, which may contribute to a
PAl-i mRNA local activity mirrors local PAT-i protein levels and reduced tendency towards capillary thrombosis and protect
effects. Inhibition of the RAS appears to shift the in vivo balance against accumulation of ECM. These combined effects may
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smooth muscle cells [18]. IL-1/3 [20] and TNF-a [19] were also
shown to induce PAT-I expression in vascular endothelial cells. In
4— PAI-1 the present study there were no significant changes in mRNA
expressions of IL-1f3, TNF-a, PDGF-B and bFGF in the kidney
after irradiation or after treatment with ACEIs or AuRA. Ex-
pression of TGF-131 mRNA was moderately increased in the
4— PA kidney at 12 weeks after irradiation, and this increase was
significantly decreased by treatment with enalapril or AuRA, but
not captopril, although all three interventions had similar benefi-
cial effects on morphologic injury. Further, TGF-/3I mRNA
.— PA expression by in situ hybridization did not colocalize with glomer-U ular lesions. Therefore, although it is possible that increased
TGF-j3I may affect PAT-i expression in the irradiated kidney
either directly or by its interactions with Ang II [171, it does not
—
G3PDH appear to be the major regulator of PAT-i and injury in this
Previous data suggest that impaired vascular function, rather
than direct radiation injury to parenchymal cells, underlies the
parenchymal cell loss and fibrosis characteristic of late radiation
injury [311. Thus, endothelial cell injury and thrombosis in capil-
laries precede myocardial fibrosis in the irradiated heart [32], and
increased vascular permeability to fibrinogen was observed in the
irradiated lung prior to fibrosis [33]. The present study confirms
that capillary endothelial injury and thrombosis precede intersti-
tial fibrosis and glomerulosclerosis, as previously shown in the
irradiated pig kidney [31•
Although ACEIs have been shown to prevent late radiation
injury in the kidney [13], as well as in lung [14] and skin [151, the
mechanisms of this effect have not been established. Although the
RAS is activated in radiation nephropathy, hypertension does not
develop until sclerosis is well established. These observations in
addition to others [35] have led to the hypothesis that nonhemo-
dynamic mechanisms of the RAS may contribute to the develop-
ment of fibrosis. Furthermore, non-Ang II effects of ACEI have
also been considered to contribute to protection against injury.
ACEIs also inhibit kininase, and thus augment local bradykinin
effects, which may contribute to protection in ischemia-reperfu-
sion injury in the infarcted heart [36]. In addition, the free radical
scavenger effect of captopril, mediated by its thiol group [371, has
been suggested as a major contributor to protection after radia-
tion injury [141. In the present study, captopril markedly reduced
both proteinuria and early histological changes at 12 weeks after
irradiation. However, enalapril, which does not contain a thiol
group, and AuRA, not reported to have scavenging effects,
showed similar efficacy. Of note, creatinine levels at 12 weeks
were similar in treated and untreated irradiated rats, likely
reflecting the insensitivity of this index of renal function. In
addition, the lower than normal blood pressure induced by Ang
inhibition may have contributed to this apparent renal dysfunction
by decreasing GFR. Studies of renal function and structure at
week 24 showed that serum creatinine levels and sclerosis were
markedly increased in untreated, but not treated irradiated rats.
The decrease in blood pressure induced by Ang inhibition may
also have contributed in part to reduced proteinuria in treated
groups. The similar results with ACEIs and AuRA strongly
suggest that the protective effect of these interventions on radia-
tion nephropathy is mediated by inhibition of the RAS.
It is likely that multiple biological mechanisms associated with
the activation of the RAS contribute to the protective effect of
ACEIs and AuRA in various vascular and renal injuries. Altered
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Fig. 4. Expression of PAl-i, t-PA, u-PA, and G3PDH mRNA expression in
the kidney at week 12 by Northern blot analysis (A) and PAI-1/G3PDH
mRNA ratio by densitometric analysis (B) (N = 5 for each group). Data are
shown in percent of mean value of control group. Treatment significantly
reduced PAl-i mRNA expression contrasting no effect on u-PA and t-PA
mRNA expression. *p < 0.05 versus untreated irradiated group (defined
P values are shown in the text). Abbreviations are: No Rx, no treatment;
Capt, captopril; Enal, enalapril; AIIRA, angiotensin II receptor antago-
nist.
underlie the observed protection against development of fibrosis
of antagonizing Ang II actions after irradiation of the kidney.
We also studied the expression of other mediators that affect
the PA/plasmin system in the irradiated kidney. In addition to
bFGF and TGF-p, PDGF induces expression of PAl-I in vascular
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hemodynamics may affect the progression of vascular injury in
some settings. Inhibition of the RAS may affect vascular perme-
ability of injured capillaries [38]. Further, inhibition of RAS may
prevent accumulation of ECM not only by accelerating degrada-
tion but also inhibiting synthesis either directly or via inhibition of
TGF-f3 [23, 39]. The present data indicate that modulation of the
PA!plasmin system may be an additional mechanism by which
inhibition of the RAS prevents tissue fibrosis after endothelial
injury.
The interaction between the RAS and PA/plasmin system
reported in this study may be relevant to other disease processes.
Vascular endothelial cells contain immunoactive renin and angio-
tensins [401, and can synthesize and secrete Ang II [41]. The RAS
is activated after endothelial injury [42], including radiation injury
[43, 44j. Further, atherosclerotic lesions in humans show in-
creased expression of ACE [45]. PAl-I expression was also
reported in the atherosclerotic artery [46], in the glomerulus of
thrombotic microangiopathy [47] and in patients with myocardial
infarction [481. ACEI treatment significantly lowered PAT-i activ-
ities in post-MI patients, although long-term benefits were not
investigated. Based on these findings, we postulate that the
interaction between RAS and PA/plasmin system may affect
fibrogenesis in diverse settings.
In conclusion, the present study demonstrates in vivo modula-
tion of PAl-I by RAS inhibition. This interaction adds yet another
facet to RAS effects, and provides an additional potential under-
lying mechanism for the effectiveness of RAS inhibition in diverse
disease settings where fibrosis may develop.
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